Physician profile
Anthony Bertelle
NPI 1598874281
$21,664.57
in general payments reported to CMS, 2019-2025
52 companies · $3,050 in 2025
The $3,050 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,424 · 2020: $2,886 · 2021: $3,502 · 2022: $3,777 · 2023: $2,767 · 2024: $2,258 · 2025: $3,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,074.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,953.88 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,741.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,650.09 | 2019-2024 | Jardiance, Cyltezo |
| Pfizer INC. | $1,448.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,392.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $1,344.09 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $1,319.60 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Lilly USA, LLC | $983.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $944.24 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $845.01 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $601.01 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Esperion Therapeutics, INC. | $593.71 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $498.11 | 2019-2022 | |
| Amarin Pharma, INC. | $468.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $466.17 | 2019-2025 | Eliquis, Camzyos |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Bertelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.